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Background
Recently a consensus was reached on the treatment of the
HCV-infected, injection drug user (IDU) with pegylated
interferon and ribavirin [1]. It is yet unclear as to whether
these best-practice guidelines have been followed to good
result due to multiple perceived barriers to treatment ini-
tiation.
Materials and methods
A systematic literature search in PubMed / MEDLINE, was
performed. Peer-reviewed journal articles investigating
barriers to treatment and therapeutic outcomes were
retrieved and critically appraised. Twenty studies identify-
ing issues related to treatment initiation and twenty-six
studies presenting therapeutic outcomes were analyzed.
Results are summarized and presented in evidence tables.
Pooling and further statistical analysis was not justified
because of heterogeneity of the identified studies.
Results
Despite being handicapped by negative views on treat-
ment eligibility, clinical studies indicate that IDUs can be
successfully treated for HCV, even in the setting of ongo-
ing drug use. Rates of sustained virological response (SVR)
were similar to control groups while patient compliance,
treatment adverse effects and potential re-infection didn't
have a significant impact on the therapeutic outcome.
Therapy can be initiated during the early phase of drug
treatment, regardless of the drug treatment strategy.
Conclusions
The evolving body of medical evidence indicates that
IDUs can be effectively treated for HCV despite the persist-
ence of putative, psychosocial barriers to treatment. Our
approach to an addicted patient who needs HCV treat-
ment, should not be clouded by perception or prejudice,
but instead focus on patient education, interdisciplinary
collaboration and close monitoring of the appropriate
biological treatment.
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